Arbitral Digest

Matter

Norton (Waterford) Limited t/a Teva Pharmaceuticals Ireland v Bristol-Myers Squibb Holdings Ireland Unlimited Company (High Court of Ireland [2023] IEHC 744)

  1. 2 November 2022Sweden

    2 November 2022Sweden

    Judgment of the Patent and Market Court in the case Teva Sweden Aktiebolag v BMS Holdings Ireland Unlimited Company dated 2 November 2022

    Patent and Market Court

    Decision summary
    The Patent and Market Court dismissed Teva Sweden Aktiebolag’s claim and ordered it to reimburse BMS Holdings for legal costs of USD 1,571,287.25, EUR 118,657, GBP 56,382 and SEK 292,652, with interest.

    Supporting details

    4 authorities · 2 participants
    Teva Sweden Aktiebolag
    Bristol-Myers Squibb Holdings Ireland Unlimited Company
    Patent and Market Court

    Authorities cited

    4
    • Swedish Patents Act (1967:837)
      statute
    • Swedish Code of Judicial Procedure
      statute
    • Swedish Interest Act (1975:635)
      statute
    • European Patent Convention (Article 87 EPC)
      treaty

    6 months and 20 days later · 201 days

  2. 22 May 2023Norway

    22 May 2023Norway

    Judgment of the Oslo District Court in the case Teva Norway AS and Anor v BMS Holdings Ireland Unlimited Company dated 22 May 2023

    Oslo District Court

    Decision summary
    The Oslo District Court found in favour of Bristol-Myers Squibb Holdings Ireland Unlimited Company in the validity dispute concerning Norwegian patent NO 328 558 B1 and supplementary protection certificate SPC/NO 2011021, and ordered Teva Pharmaceutical Industries Ltd and Teva Norway AS to pay joint and several legal costs of NOK 9,555,655 and their share of expert lay-judge costs.

    Supporting details

    2 authorities · 4 participants
    Teva Pharmaceutical Industries Ltd
    Teva Norway AS
    Bristol-Myers Squibb Holdings Ireland Unlimited Company
    Oslo District Court

    Authorities cited

    2
    • Norwegian Civil Procedure Act
      statute
    • Norwegian Court Fees Act
      statute

    17 days later · 17 days

  3. 8 June 2023France

    8 June 2023France

    Judgment of the Judicial Court of Paris in the case S.A.S. Teva Santé v BMS Holdings Ireland Unlimited Company dated 8 June 2023

    Judicial Court of Paris

    Decision summary
    The Judicial Court of Paris dismissed Teva Santé’s claims seeking nullity of the French part of European patent EP 1 427 415 and supplementary protection certificate FR11C0042, and ordered Teva Santé to pay costs and €200,000 to BMS Holdings.

    Supporting details

    3 authorities · 2 participants
    S.A.S. Teva Santé
    Bristol-Myers Squibb Holdings Ireland Unlimited Company
    Judicial Court of Paris

    Authorities cited

    3
    • French Code of Civil Procedure
      statute
    • French Commercial Code
      statute
    • European Patent Convention (Articles 83 and 138(1)(b) EPC)
      treaty

    2 months and 7 days later · 68 days

  4. 15 August 2023The Netherlands

    15 August 2023The Netherlands

    Judgment of the Court of Appeal of The Hague in the case BMS Holdings Ireland Unlimited Co v Sandoz BV dated 15 August 2023

    Court of Appeal of The Hague

    Decision summary
    The Court of Appeal of The Hague set aside the preliminary-relief judgment and ordered the defendants to cease infringement of BMS’s supplementary protection certificate, remove generic apixaban products from the G-standard, provide supply information, recall infringing products, and pay costs, subject to penalties.

    Supporting details

    3 authorities · 5 participants
    Bristol-Myers Squibb Holdings Ireland Unlimited Company
    Sandoz BV
    Court of Appeal of The Hague

    Authorities cited

    3
    • Dutch Code of Civil Procedure
      statute
    • Charter of Fundamental Rights of the European Union (Articles 16 and 17(2) of the Charter)
      treaty
    • Decision G2/21 of the Enlarged Board of Appeal of the European Patent Office, 23 March 2023 (G2/21)
      case

    3 months and 23 days later · 115 days

  5. 8 December 2023Ireland

    8 December 2023Ireland

    Judgment of the High Court of Ireland in the case [2021 No. 1 PAP], [2021 No. 3 PAP], [2021 No. 4758 P] and [2021 No. 4759 P] dated 8 December 2023

    High Court of Ireland

    Decision summary
    The High Court held that Irish Patent EP (IE) 1 427 415 was invalid, while concluding that, if valid, Delaware law would give it the claimed priority date. The judgment addressed priority entitlement, patent validity, novelty, inventive step, sufficiency, and the supplementary protection certificate.

    Supporting details

    42 authorities · 3 participants
    Norton (Waterford) Limited trading as Teva Pharmaceuticals Ireland
    Bristol-Myers Squibb Holdings Ireland Unlimited Company
    High Court of Ireland

    Authorities cited

    42
    • Patents Act 1992 to 2019
      statute
    • United States Patent Code, Title 35 (35 USC §261)
      statute
    • Delaware Code §220
      statute
    • European Patent Convention (Article 87 EPC)
      treaty
    • Case G-0005/83 (Second medical indication) (ECLI:EP:BA:1984:G000583.19841205) (ECLI:EP:BA:1984:G000583.19841205)
      case
    • Case J-0019/87 Assignee (ECLI:EP:BA:1988:J001987.19880321) (ECLI:EP:BA:1988:J001987.19880321)
      case
    • Case G-0004/88 Transfer of opposition (ECLI:EP:BA:1989:G000488.19890424) (ECLI:EP:BA:1989:G000488.19890424)
      case
    • Case T-0939/92 Triazoles/AGREVO (ECLI:EP:BA:1995:T093992.19950912) (ECLI:EP:BA:1995:T093992.19950912)
      case
    • Case T-0590/98 Radiopharmaceuticals/AMERSHAM PLC (ECLI:EP:BA:2003:T059098.20030430) (ECLI:EP:BA:2003:T059098.20030430)
      case
    • Case T-1329/04 Factor-9/JOHN HOPKINS (ECLI:EP:BA:2005:T132904.20050628) (ECLI:EP:BA:2005:T132904.20050628)
      case
    • Case T-578/06 Pancreatic cells/IPSEN (ECLI:EP:BA:2011:T057806.20110629) (ECLI:EP:BA:2011:T057806.20110629)
      case
    • Case T-1642/07 Viral enhancement of cell killing/Arch Development Corporation (ECLI:EP:BA:2010:T164207.20101202) (ECLI:EP:BA:2010:T164207.20101202)
      case
    • Case T-0577/11 Entitlement to priority (ECLI:EP:BA:2016:T057711.20160414) (ECLI:EP:BA:2016:T057711.20160414)
      case
    • Case T-0205/14 Ibandronate sodium, Form QQ/Teva (ECLI:EP:BA:2015:T020514.20150618) (ECLI:EP:BA:2015:T020514.20150618)
      case
    • Case T-1201/14 Transfer of right of priority (ECLI:EP:BA:2017:T120114.20170209) (ECLI:EP:BA:2017:T120114.20170209)
      case
    • Case T-1103/15 University of Alabama (ECLI:EP:BA:2018:T110315.20180222) (ECLI:EP:BA:2018:T110315.20180222)
      case
    • Case T-1786/15 BMP Antagonists/General Hospital Corporation (ECLI:EP:BA:2020:T178615.20201015) (ECLI:EP:BA:2020:T178615.20201015)
      case
    • Case T-0488/16 Dasatinib/BMS (ECLI:EP:BA:2017:T048816.20170201) (ECLI:EP:BA:2017:T048816.20170201)
      case
    • Case T-1322/17 Ibandronate/ATNAHS (ECLI:EP:BA:2019:T132217.20190319) (ECLI:EP:BA:2019:T132217.20190319)
      case
    • Case G-0002/21 Insecticide compositions/Sumitomo (ECLI:EP:BA:2023:G000221.20230323) (ECLI:EP:BA:2023:G000221.20230323)
      case
    • Accord Healthcare Ltd v Research Corporation Technologies [2017] EWHC 2711 (Ch) ([2017] EWHC 2711 (Ch))
      case
    • HTC Corp v Gemalto SA [2013] EWHC 1876 (Pat.) ([2013] EWHC 1876 (Pat.))
      case
    • Sandoz Ltd v BMS Holdings Ireland Unlimited Co. [2022] EWHC 822 (Pat.) ([2022] EWHC 822 (Pat.))
      case
    • Warner-Lambert Co LLC v Generics (UK) Ltd [2018] UKSC 56 ([2018] UKSC 56)
      case
    • Norton (Waterford) Ltd t/a Teva Pharmaceuticals Ltd v Boehringer Ingelheim Pharma GmbH & Co. KG [2022] IECA 58 ([2022] IECA 58)
      case
    • Ranbaxy Laboratories Ltd v Warner-Lambert Co [2007] IEHC 256 ([2007] IEHC 256)
      case
    • Re Boehringer Ingelheim Pharma GmbH [2017] IEHC 495 ([2017] IEHC 495)
      case
    • Jim Arnold Corp v Hydrotech Systems Inc, 109 F.3d 1567 (1997) (109 F.3d 1567 (1997))
      case
    • Schwendimann v Arkwright Advanced Coating Inc, 959 F.3d 1065 (Fed. Cir. 2020) (959 F.3d 1065 (Fed. Cir. 2020))
      case
    • Dalzell v Dueber Watch-Case Mfg. Co., 149 U.S. 315 (1893) (149 U.S. 315 (1893))
      case
    • Beam Laser Systems, Inc. v Cox Communications, Inc., 117 F.Supp.2d 515 (E.D. Va. 2000) (117 F.Supp.2d 515 (E.D. Va. 2000))
      case
    • Digitech Image Techs LLC v Newegg Inc., 2013 WL 1871513 (C.D. Cal. 2013) (2013 WL 1871513 (C.D. Cal. 2013))
      case
    • Akazawa v Link New Technology International Inc., 520 F.3d 1354 (2008) (520 F.3d 1354 (2008))
      case
    • Enovsys LLC v Nextel Communications Inc., 614 F.3d 1333 (2010) (614 F.3d 1333 (2010))
      case
    • Abraxis Bioscience Inc v Navinta LLC, 625 F.3d 1359 (2010) (625 F.3d 1359 (2010))
      case
    • Board of Trustees of the Leland Stanford Junior University v Roche Molecular Systems, Inc., 583 F.3d 832 (Fed. Cir. 2009) (583 F.3d 832 (Fed. Cir. 2009))
      case
    • Hewett v Samsonite Corp., 507 P.2d 1119 (Colo. App. 1973) (507 P.2d 1119 (Colo. App. 1973))
      case
    • My Mail Limited v America Online Inc., 476 F.3d 1372 (476 F.3d 1372)
      case
    • Ager v Murray, 105 U.S. 126 (1881) (105 U.S. 126 (1881))
      case
    • BMS Holdings Ireland Unlimited Co v Sandoz BV and ors, Court of Appeal of The Hague, 15th August 2023 (Court of Appeal of The Hague, 15th August 2023)
      case
    • Teva Norway AS and Anor v BMS Holdings Ireland Unlimited Company, Oslo District Court, 22nd May 2023 (Oslo District Court, 22nd May 2023)
      case
    • Teva Sweden Aktiebolag v BMS Holdings Ireland Unlimited Company, 2nd November 2022 (2nd November 2022)
      case

Matter record

Report a correction

Norton (Waterford) Limited t/a Teva Pharmaceuticals Ireland v Bristol-Myers Squibb Holdings Ireland Unlimited Company (High Court of Ireland [2023] IEHC 744) · Matter